Page 7 - Nuclear Export News Today

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

The pCPA agreement will support the public listings and reimbursement of XPOVIO. XPOVIO represents the first new drug class for the treatment of early relapsed or refractory multiple myeloma introduced

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

StockNews.com began coverage on shares of Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) in a report published on Thursday. The brokerage issued a hold rating on the stock. KPTI has been the topic of a number of other research reports. Piper Sandler began coverage on Karyopharm Therapeutics in a research report on Thursday, January 19th. They […]

StockNews.com initiated coverage on shares of Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) in a research report released on Thursday morning. The brokerage issued a hold rating on the stock. Other research analysts have also recently issued research reports about the stock. Morgan Stanley decreased their target price on shares of Karyopharm Therapeutics from $7.00 to […]

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) has been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year target […]

Monashee Investment Management LLC purchased a new position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 481,696 shares of the company’s stock, valued at approximately $1,638,000. Other hedge funds and other institutional investors have also recently added […]

Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) had its target price lowered by Robert W. Baird from $14.00 to $10.00 in a research report sent to investors on Friday, The Fly reports. A number of other research analysts have also issued reports on KPTI. HC Wainwright lowered their target price on Karyopharm Therapeutics from $16.00 to […]

Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) had its price objective cut by HC Wainwright from $16.00 to $10.00 in a research note released on Friday, The Fly reports. Other research analysts also recently issued reports about the stock. Morgan Stanley lowered their price target on shares of Karyopharm Therapeutics from $7.00 to $5.00 and set […]

Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) had its price target lowered by HC Wainwright from $16.00 to $10.00 in a research note released on Friday, The Fly reports. A number of other analysts have also recently issued reports on the company. Morgan Stanley dropped their price objective on Karyopharm Therapeutics from $7.00 to $5.00 and […]